Journal article
Efficacy of Single-Dose Azithromycin in Treatment of Acute Otitis Media in Children after a Baseline Tympanocentesis
Antimicrobial agents and chemotherapy, v 47(8), pp 2663-2665
Aug 2003
PMID: 12878537
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Children with acute otitis media underwent tympanocentesis and were given a single dose of 30 mg of azithromycin/kg of body weight. At day 28, the overall clinical cure rate was 206 of 242 (85%). Clinical cure rates for patients infected with
Streptococcus pneumoniae
(67 of 76; 88%) and
Haemophilus influenzae
(28 of 44; 64%) were consistent with historical rates for the 5-day dosing regimen.
Metrics
Details
- Title
- Efficacy of Single-Dose Azithromycin in Treatment of Acute Otitis Media in Children after a Baseline Tympanocentesis
- Creators
- Michael W Dunne - Pfizer Global Research & Development, New London, ConnecticutChandra Khurana - Pfizer Global Research & Development, New London, ConnecticutAdriano Arguedas Mohs - Pfizer Global Research & Development, New London, ConnecticutAdib Rodriguez - Pfizer Global Research & Development, New London, ConnecticutAntonio Arrieta - Pfizer Global Research & Development, New London, ConnecticutSamuel McLinn - Pfizer Global Research & Development, New London, ConnecticutJudy A Krogstad - Pfizer Global Research & Development, New London, ConnecticutMark Blatter - Pfizer Global Research & Development, New London, ConnecticutRichard Schwartz - Pfizer Global Research & Development, New London, ConnecticutSergio L Vargas - Pfizer Global Research & Development, New London, ConnecticutPaz Emparanza - Pfizer Global Research & Development, New London, ConnecticutPilar Fernandez - Pfizer Global Research & Development, New London, ConnecticutWillis M Gooch III - Pfizer Global Research & Development, New London, ConnecticutMary Aspin - Pfizer Global Research & Development, New London, ConnecticutJohn Podgore - Pfizer Global Research & Development, New London, ConnecticutIrmeli Roine - Pfizer Global Research & Development, New London, ConnecticutJeffrey L Blumer - Pfizer Global Research & Development, New London, ConnecticutGarth D Ehrlich - Pfizer Global Research & Development, New London, ConnecticutJean Chow - Pfizer Global Research & Development, New London, Connecticut
- Publication Details
- Antimicrobial agents and chemotherapy, v 47(8), pp 2663-2665
- Publisher
- American Society for Microbiology
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000184449800044
- Scopus ID
- 2-s2.0-0042267996
- Other Identifier
- 991014969864504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Microbiology
- Pharmacology & Pharmacy